PE20190376A1 - Combinaciones farmaceuticas para el tratamiento del cancer - Google Patents
Combinaciones farmaceuticas para el tratamiento del cancerInfo
- Publication number
- PE20190376A1 PE20190376A1 PE2018003179A PE2018003179A PE20190376A1 PE 20190376 A1 PE20190376 A1 PE 20190376A1 PE 2018003179 A PE2018003179 A PE 2018003179A PE 2018003179 A PE2018003179 A PE 2018003179A PE 20190376 A1 PE20190376 A1 PE 20190376A1
- Authority
- PE
- Peru
- Prior art keywords
- aryl
- cancer
- aralkyl
- treatment
- hydrogen
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 229940126033 PPAR agonist Drugs 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 abstract 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 abstract 2
- 239000012826 P38 inhibitor Substances 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- -1 cycloalkyalkyl Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 abstract 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract 1
- JYYLVUFNAHSSFE-UHFFFAOYSA-N pamapimod Chemical group O=C1N(C)C2=NC(NC(CCO)CCO)=NC=C2C=C1OC1=CC=C(F)C=C1F JYYLVUFNAHSSFE-UHFFFAOYSA-N 0.000 abstract 1
- 229950001749 pamapimod Drugs 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 229960005095 pioglitazone Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Se refiere a una combinacion farmaceutica que comprende: (a) un agonista de PPAR; (b) un inhibidor de la quinasa p38 de Formula I o II o sus sales; y opcionalmente (c) uno o mas sustituyentes, excipientes o portadores aceptables farmaceuticamente. Respecto a las formulas I o II, se tiene que Z es N o CH; W es NR2; X1 es O, NR4, S, o CR5R6 o C=O; X2 es O o NR7; Ar1 es arilo o heteroarilo; R1 es hidrogeno, haloalquilo, arilo, aralquilo, heteroarilo, entre otros; R3 es hidrogeno, alquilo, cicloalquilo, cicloalquialquilo, arilo, aralquilo, entre otros; R8 y R9 son hidrogeno, alquilo, arilo, aralquilo, cicloalquilo, entre otros. De preferencia el agonista PPAR es la pioglitazona y el inhibidor p38 es el pamapimod. Esta combinacion farmaceutica es util para la prevencion, el retraso de la progresion o el tratamiento del cancer de pulmon, ovario, prostata, entre otros.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16173443 | 2016-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190376A1 true PE20190376A1 (es) | 2019-03-08 |
Family
ID=56132777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018003179A PE20190376A1 (es) | 2016-06-08 | 2017-06-06 | Combinaciones farmaceuticas para el tratamiento del cancer |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11285155B2 (es) |
| EP (1) | EP3468604B1 (es) |
| JP (2) | JP7349790B2 (es) |
| KR (1) | KR102437685B1 (es) |
| CN (2) | CN115105601A (es) |
| AU (1) | AU2017277478B2 (es) |
| BR (1) | BR112018075135A2 (es) |
| CA (1) | CA3023392C (es) |
| CL (1) | CL2018003509A1 (es) |
| CO (1) | CO2018013020A2 (es) |
| CY (1) | CY1124123T1 (es) |
| DK (1) | DK3468604T3 (es) |
| EA (1) | EA201892287A1 (es) |
| ES (1) | ES2866883T3 (es) |
| HU (1) | HUE053648T2 (es) |
| IL (1) | IL263407B (es) |
| MX (1) | MX379026B (es) |
| MY (1) | MY195671A (es) |
| PE (1) | PE20190376A1 (es) |
| PH (1) | PH12018550186A1 (es) |
| PL (1) | PL3468604T3 (es) |
| PT (1) | PT3468604T (es) |
| SG (1) | SG11201809882XA (es) |
| UA (1) | UA123914C2 (es) |
| WO (1) | WO2017211830A1 (es) |
| ZA (1) | ZA201900052B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017019170A2 (pt) | 2015-03-09 | 2018-07-10 | Intekrin Therapeutics, Inc. | métodos para o tratamento de doença do fígado gorduroso não alcoólico e / ou lipodistrofia |
| AU2017277478B2 (en) * | 2016-06-08 | 2023-03-16 | Support-Venture Gmbh | Pharmaceutical combinations for treating cancer |
| SG11201900776TA (en) * | 2016-08-17 | 2019-03-28 | Support Venture Gmbh | Method of preventing or treating hearing loss |
| MX2019001979A (es) * | 2016-08-18 | 2019-09-19 | Intekrin Therapeutics Inc | Agonista de ppar? para el tratamiento de neoplasias hematicas. |
| US11253508B2 (en) | 2017-04-03 | 2022-02-22 | Coherus Biosciences, Inc. | PPARy agonist for treatment of progressive supranuclear palsy |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| CN111601593B (zh) | 2017-10-05 | 2022-04-15 | 弗尔康医疗公司 | P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd |
| JP2021524493A (ja) * | 2018-07-13 | 2021-09-13 | キナラス アーゲー | 線維性疾患を予防または処置するためのＰＰＡＲアゴニストおよびｐ３８キナーゼ阻害剤の組合せ物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| JP4064818B2 (ja) * | 2001-02-12 | 2008-03-19 | エフ．ホフマン−ラ ロシュ アーゲー | ６−置換ピリド−ピリミジン類 |
| US6852141B2 (en) * | 2001-06-06 | 2005-02-08 | Donaldson Company, Inc. | Filter element having center piece and methods |
| CN1771034A (zh) * | 2002-01-14 | 2006-05-10 | 法马西亚公司 | 过氧化物酶体增殖物激活受体－α激动剂和环加氧酶－2选择性抑制剂的组合及其治疗用途 |
| US20030212138A1 (en) * | 2002-01-14 | 2003-11-13 | Pharmacia Corporation | Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor |
| RU2348632C2 (ru) | 2003-11-13 | 2009-03-10 | Ф.Хоффманн-Ля Рош Аг | Гидроксиалкилзамещенные пиридо-7-пиримидин-7-оны |
| US20090074676A1 (en) * | 2005-05-23 | 2009-03-19 | Smithkline Beecham Corporation | Inhibition of p38 MAPK For Treatment Of Obesity |
| WO2007146712A2 (en) | 2006-06-09 | 2007-12-21 | Kemia, Inc. | Therapy using cytokine inhibitors |
| CN101679211A (zh) | 2007-06-15 | 2010-03-24 | 霍夫曼-拉罗奇有限公司 | 用于制备3-氨基-戊-1,5-二醇的新方法 |
| EP2379174A4 (en) * | 2008-12-18 | 2012-11-14 | Astrazeneca Ab | PHARMACEUTICAL PRODUCT USING A P38 KINASE INHIBITOR AND A SECOND ACTIVE SUBSTANCE |
| CA2789847A1 (en) * | 2010-02-15 | 2011-08-18 | Synovo Gmbh | Kinase modulators for the treatment of cancer |
| AU2017277478B2 (en) * | 2016-06-08 | 2023-03-16 | Support-Venture Gmbh | Pharmaceutical combinations for treating cancer |
-
2017
- 2017-06-06 AU AU2017277478A patent/AU2017277478B2/en not_active Ceased
- 2017-06-06 CA CA3023392A patent/CA3023392C/en active Active
- 2017-06-06 BR BR112018075135-9A patent/BR112018075135A2/pt not_active Application Discontinuation
- 2017-06-06 DK DK17726974.3T patent/DK3468604T3/da active
- 2017-06-06 UA UAA201811166A patent/UA123914C2/uk unknown
- 2017-06-06 HU HUE17726974A patent/HUE053648T2/hu unknown
- 2017-06-06 MY MYPI2018001959A patent/MY195671A/en unknown
- 2017-06-06 KR KR1020187034097A patent/KR102437685B1/ko active Active
- 2017-06-06 EA EA201892287A patent/EA201892287A1/ru unknown
- 2017-06-06 PL PL17726974T patent/PL3468604T3/pl unknown
- 2017-06-06 PE PE2018003179A patent/PE20190376A1/es unknown
- 2017-06-06 CN CN202210619102.6A patent/CN115105601A/zh active Pending
- 2017-06-06 MX MX2018014938A patent/MX379026B/es unknown
- 2017-06-06 JP JP2018564408A patent/JP7349790B2/ja active Active
- 2017-06-06 WO PCT/EP2017/063714 patent/WO2017211830A1/en not_active Ceased
- 2017-06-06 EP EP17726974.3A patent/EP3468604B1/en active Active
- 2017-06-06 SG SG11201809882XA patent/SG11201809882XA/en unknown
- 2017-06-06 CN CN201780035298.1A patent/CN109414506B/zh not_active Expired - Fee Related
- 2017-06-06 ES ES17726974T patent/ES2866883T3/es active Active
- 2017-06-06 US US16/307,860 patent/US11285155B2/en active Active
- 2017-06-06 PT PT177269743T patent/PT3468604T/pt unknown
-
2018
- 2018-11-14 PH PH12018550186A patent/PH12018550186A1/en unknown
- 2018-11-30 CO CONC2018/0013020A patent/CO2018013020A2/es unknown
- 2018-12-02 IL IL263407A patent/IL263407B/en unknown
- 2018-12-06 CL CL2018003509A patent/CL2018003509A1/es unknown
-
2019
- 2019-01-04 ZA ZA2019/00052A patent/ZA201900052B/en unknown
-
2021
- 2021-04-07 CY CY20211100295T patent/CY1124123T1/el unknown
- 2021-12-10 JP JP2021200752A patent/JP2022046526A/ja active Pending
-
2022
- 2022-02-22 US US17/677,180 patent/US20220175786A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190376A1 (es) | Combinaciones farmaceuticas para el tratamiento del cancer | |
| CY1124737T1 (el) | Ανταγωνιστες lpa | |
| CY1124046T1 (el) | Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος | |
| DOP2022000117A (es) | Inhibidores de kras g12c | |
| MX2023001876A (es) | Derivados de rapamicina. | |
| CY1121694T1 (el) | Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4 | |
| MX2018013433A (es) | Piperidinas como inhibidores de menina. | |
| UY36122A (es) | ?derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1? | |
| MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
| EA202091505A1 (ru) | Триазолазолы циклогексильной кислоты в качестве антагонистов lpa | |
| BR112017024917A2 (pt) | síntese de compostos heterocíclicos | |
| MX2018002402A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4). | |
| MX2019007243A (es) | Inhibidores de ectonucleotidasa y metodos de uso de los mismos. | |
| MX2017002670A (es) | Inhibidores de glucosidasa. | |
| CU24419B1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas | |
| UY35617A (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| EA201992320A1 (ru) | Пиперидины в качестве ковалентных ингибиторов менина | |
| PE20161236A1 (es) | Compuesto de triazina y su uso para fines medicos | |
| AR102981A1 (es) | Inhibidores de la necrosis celular y métodos de preparación de los mismos | |
| CL2019000662A1 (es) | Inhibidores de dopamina–b–hidroxilasa. | |
| CY1120142T1 (el) | Ενωσεις αζετιδινυλοξυφαινυλοπυρρολiδινης | |
| CO2017000011A2 (es) | Derivados de quinolizinona como inhibidores de pi3k | |
| CO2018004213A2 (es) | Compuesto piranodipiridínico | |
| CL2019001804A1 (es) | Activador de nrf2. | |
| SV2016005310A (es) | Derivados de diheterociclo enlazado a cicloalquilo |